Marco Dioguardi Burgio

Université Paris Cité
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

A deep learning algorithm achieved liver metastasis detection rates on contrast-enhanced abdominal CT scans comparable to those of radiologists, with consistent performance across different lesion sizes, locations, and clinical conditions.

Year:

2026

Year:

2026

Background and Aims: Noninvasive tools assessing steatosis, such as ultrasonography-based 2D-attenuation imaging (ATI), are needed to tackle the worldwide burden of steatotic liver disease. This one-stage individual patient data (IPD) meta-analysis aimed to create an ATI-based steatosis grading system. Approach and Results: A systematic review (EMBASE + MEDLINE, 2018–2022) identified studies, including patients with histologically or magnetic resonance imaging proton-density fat fraction (MRI-PDFF)–verified ATI for grading steatosis (S0 to S3). One-stage IPD meta-analyses were conducted using generalized mixed models with a random study-specific intercept. Created ATI-based steatosis grading system (aS0 to aS3) was externally validated on a prospective cohort of patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (n=174, histologically and MRI-PDFF–verified steatosis). Eleven enrolled studies included 1374 patients, classified into S0, S1, S2, and S3 in 45.4%, 35.0%, 9.3%, and 10.3% of the cases. ATI was correlated with histological steatosis ( r = 0.60; 95% CI: 0.52, 0.67; p < 0.001) and MRI-PDFF ( r = 0.70; 95% CI: 0.66, 0.73; p < 0.001) but not with liver stiffness ( r = 0.03; 95% CI: −0.04, 0.11, p = 0.343). Steatosis grade was an independent factor associated with ATI (coefficient: 0.24; 95% CI: [0.22, 0.26]; p < 0.001). ATI marginal means within S0, S1, S2, and S3 subpopulations were 0.59 (95% CI: [0.58, 0.61]), 0.69 (95% CI [0.67, 0.71]), 0.78 (95% CI: [0.76, 0.81]), and 0.85 (95% CI: [0.83, 0.88]) dB/cm/MHz; all contrasts between grades were significant ( p < 0.0001). Three ATI thresholds were calibrated to create a new ATI-based steatosis grading system (aS0 to aS3, cutoffs: 0.66, 0.73, and 0.81 dB/cm/MHz). Its external validation showed Obuchowski measures of 0.84 ± 0.02 and 0.82 ± 0.02 with histologically based and MRI-PDFF–based references. Conclusions: ATI is a reliable, noninvasive marker of steatosis. This validated ATI-based steatosis grading system could be valuable in assessing patients with metabolic dysfunction–associated steatotic liver disease.

Year:

2025

This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), are emerging as leading causes of hepatocellular carcinoma (HCC) development. This has important implications for evaluating patients with these conditions, including the potential for early diagnosis through screening techniques. Imaging techniques for the noninvasive diagnosis of HCC in the context of MASLD also present unique considerations. Notably, HCC development in patients without cirrhosis is more frequent in MASLD compared to other chronic liver disease etiologies. Moreover, the presence of liver steatosis, a common feature in MASLD patients, can modify the radiological appearance of the liver, giving HCC in MASLD/MASH uncommon imaging characteristics. Additionally, certain histological subtypes, particularly the steatohepatitic HCC, are more prevalent in MASLD/MASH, which may influence both diagnostic strategies and therapeutic decisions in these patients. This review article focuses on the radiological characteristics of HCC developed in patients with MASLD/MASH. It specifically addresses the roles of screening and surveillance, the radiological features of HCC in MASLD/MASH, the histological subtypes associated with these conditions, and the impact of imaging on treatment decisions. Finally, a brief summary of future directions and the role of new technologies in HCC diagnosis within the context of MASLD is provided.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (14)

Lucia Parlati

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Christian B. van der Pol

-

CANADA
View details

Anita Paisant

-

FRANCE
View details

Thomas Karlas

University Hospital Leipzig

GERMANY
View details

Jeong Min Lee

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Hyo-Jin Kang

Seoul National University Hospital

SOUTH KOREA
View details

Philip Newsome

Director of Roger Williams Institute of Liver Studies

University of Birmingham

UNITED KINGDOM
View details

Federica Vernuccio

Docenti di ruolo di IIa fascia

University of Palermo

ITALY
View details

Andreu Costa

college of pharmacy dalhousie university halifax nova scotia canada

CANADA
View details

Cédric LAOUENAN

Professor

Université Paris-Saclay

FRANCE
View details

Florent Besson

Professor (PU-PH)

Université Paris-Saclay

FRANCE
View details

Emmanuel Tsochatzis

Professor of Hepatology and Consultant Hepatologist

University College London

UNITED KINGDOM
View details

Christian Hobeika

MCU-PH

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Edward Grant

Professor

University of Southern California

UNITED STATES
View details